- Home
- DERM vs IKT Comparison
DERM vs IKT Comparison
Compare DERM & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DERM
- IKT
- Stock Information
- Founded
- DERM 2014
- IKT 2008
- Country
- DERM United States
- IKT United States
- Employees
- DERM N/A
- IKT N/A
- Industry
- DERM Biotechnology: Pharmaceutical Preparations
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- DERM Health Care
- IKT Health Care
- Exchange
- DERM Nasdaq
- IKT Nasdaq
- Market Cap
- DERM 140.0M
- IKT 167.2M
- IPO Year
- DERM 2021
- IKT 2020
- Fundamental
- Price
- DERM $6.25
- IKT $1.90
- Analyst Decision
- DERM Strong Buy
- IKT Buy
- Analyst Count
- DERM 2
- IKT 2
- Target Price
- DERM $10.00
- IKT $8.00
- AVG Volume (30 Days)
- DERM 103.6K
- IKT 147.0K
- Earning Date
- DERM 05-12-2025
- IKT 05-14-2025
- Dividend Yield
- DERM N/A
- IKT N/A
- EPS Growth
- DERM N/A
- IKT N/A
- EPS
- DERM N/A
- IKT N/A
- Revenue
- DERM $56,134,000.00
- IKT N/A
- Revenue This Year
- DERM $29.83
- IKT N/A
- Revenue Next Year
- DERM $54.88
- IKT N/A
- P/E Ratio
- DERM N/A
- IKT N/A
- Revenue Growth
- DERM N/A
- IKT N/A
- 52 Week Low
- DERM $3.20
- IKT $1.12
- 52 Week High
- DERM $7.29
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- DERM 53.65
- IKT 42.84
- Support Level
- DERM $5.98
- IKT $1.58
- Resistance Level
- DERM $6.40
- IKT $2.22
- Average True Range (ATR)
- DERM 0.62
- IKT 0.22
- MACD
- DERM -0.06
- IKT 0.00
- Stochastic Oscillator
- DERM 36.97
- IKT 45.57
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.